Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CPB1 | P15086 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 3/20 | 0.52 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSS | P25774 | 2/20 | 0.52 |
| ▸ | CTSL | P07711 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13917140 | 1.00 | EPHX1 (0.58) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL5749471 | 1.00 | EPHX1 (0.58) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL760437 | 1.00 | EPHX1 (0.58) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL18544232 | 1.00 | EPHX1 (0.58) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL13326281 | 1.00 | EPHX1 (0.58) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL31064941 | 0.97 | ALDH1A1 (0.57) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL5896898 | 0.97 | ALDH1A1 (0.57) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL5897664 | 0.97 | ALDH1A1 (0.57) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL5896895 | 0.97 | ALDH1A1 (0.57) | EPHX1ALDH1A1GAACPB1TSHR | |
| SCHEMBL5897658 | 0.97 | ALDH1A1 (0.57) | EPHX1ALDH1A1GAACPB1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-8987504-B2 | Aminohydroxylation of alkenes | VICTORIA LINK LIMITED (NZ) | 2015-03-24 | — | — | US | disclosed |
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2013-10-17 | — | — | US | disclosed |
| WO-2011159177-A1 | IMPROVED AMINOHYDROXYLATION OF ALKENES | INDUSTRIAL RESEARCH LIMITED (NZ) | 2011-12-22 | — | — | WO | disclosed |
| US-7141586-B2 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1651609-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009966-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274479-A1 | AMINOHYDROXYLATION OF ALKENES | ALKBH3, ALKBH1, ALKBH2 | EPHX1 366/4885ALDH1A1 197/4885GAA 2330/4885 |
| US-20050032838-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | CBR3, CBR1, PDE9A | EPHX1 1055/4885ALDH1A1 1353/4885GAA 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.